October 15, 2010
Edge Therapeutics Raises $72.5 Million
Through Successive Series C-1 and C-2 Financings
Precisa, our proprietary, programmable, biodegradable polymer-based development platform, enables creation of polymer-based therapeutics capable of delivering directly to the site of injury.
Our lead product candidate, EG-1962, is a polymer-based microparticle containing nimodipine developed with the Precisa platform to improve patient outcomes after Aneurysmal Subarachnoid Hemorrhage.